NFE2L2 and neoplasm: The results revealed that the triple-drug combination markedly inhibited the protein expression of VEGF, VEGFR, PI3K, p-AKT, PDK, p-mTOR, Nrf2 and HIF-1α when compared to that of tumor-control (p < 0.001) (Figure 3C); while it significantly enhanced the expression of PTEN.